From bench to the bedside

Development of a new medicine is a complicated and long-lasting pro­cess, which starts from specifying some needs, through drug designing and R&D phases, all the way to drug implementation. The pro­cess involves mul­ti­disciplinary and extensive research. Many pre-clinical, then clinical experiments (phase II and phase III) must be successfuly concluded before a new medicine -- including a new ra­dio­phar­ma­ceu­tical --  may be entered to clinical use. The experiments must prove that the medicine is safe and efficiently performs its planned dia­gno­stic or therapeutic function. Usually such a process takes from 8 to 14 years and requires financial outlays on the order of € 1 billion. Current legal regulations are by no means facilitating completion of the process.

The presentation will illustrate the R&D pro­cess on an example of a new radipharmaceutical dedicated to dia­gno­stics of medullar thyroid cancer. Such cancer exhibits a high affinity to the CCK2-R cho­le­cy­sto­ki­nin re­cep­to­rs. The radipharmaceutical belongs to the gruop of orphan drugs used to treat rare diseases. The drug ic currently under development by an international scientific consortium. POLATOM Radiopharmaceutical Centre, a partner in that consortium, is responsible for development of the drug pharmaceutical form (among others).

The conversatory class will be held in room 208 in the Świerk Science & Techology Park building. NCBJ bus leaves to Świerk at 10.25 am from entrance gate to the Hoża 69 premises in Warsaw.
Professor Ludwik Dobrzyński